2 news items
Gossamer Bio Secures $160M Partnership with Chiesi Group to Accelerate Development of Pulmonary Hypertension Treatment, $486M Potential for Seralutinib Collaboration
GOSS
6 May 24
to using innovation to promote the health and well-being of people around the world and we are proud to add this collaboration as a key pillar to our
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
GOSS
6 May 24
, Group CEO of Chiesi. "Gossamer shares Chiesi's commitment to using innovation to promote the health and well-being of people around the world and we
- Prev
- 1
- Next